2016 Fiscal Year Final Research Report
Development and characterization of a cancer-specific monoclonal antibody (CasMab) against podoplanin
| Project/Area Number |
26440019
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Structural biochemistry
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Kaneko Mika 東北大学, 医学系研究科, 准教授 (00323163)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KUNITA Akiko 東京大学, 大学院医学系研究科, 助教 (50608768)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | CasMab / PDPN / 腫瘍型糖鎖構造 / 糖転移酵素遺伝子 / 抗体医薬開発 |
|---|
| Outline of Final Research Achievements |
Podoplanin (PDPN) is a platelet aggregation-inducing mucin-like sialoglycoprotein that is highly expressed in many cancers and normal tissues. PDPN has also been reported to be a marker to enrich tumor-initiating cells. Recently, we established the platform to produce a cancer-specific mAb (CasMab) by combining glycobiology and cell engineering technologies. In this study, we also established glycan-deficient CHO-S and HEK-293T cell lines, using the CRISPR/Cas or TALEN. We investigate several novel cancer-specific anti-PDPN or anti-glycopeptide mAbs. Antitumor activity of chimeric anti-human PDPN antibodies were validated. The CasMab-producing platform could lead to establishment of the side effect-reducing mAbs.
|
| Free Research Field |
糖鎖生物学
|
